Nitric oxide and lung surfactant

https://doi.org/10.1016/S0146-0005(96)80046-2Get rights and content

Inhalation of nitric oxide (NO) is an experimental treatment for severe pulmonary hypertension. Being rapidly metabolized by hemoglobin, inhaled NO causes selective vasodilation in the pulmonary vascular bed. In addition to the vascular smooth, muscle, other pulmonary structures are exposed to inhaled NO, resulting in suppression of NO synthesis in a variety of pulmonary cells and in potential toxicity. NO is a free radical that interacts with a number of proteins, particularly metalloproteins. Together with superoxide radical, it rapidly forms highly toxic peroxynitrite. Peroxynitrite is involved in the killing of microbes by activated phagocytosing macrophages. In severe inflammation, peroxynitrite may be responsible for damaging proteins lipids, and DNA. Peroxynitrite added to surfactant in vitro is capable of decreasing the surface activity, inducing lipid peroxidation, decreasing the function of surfactant proteins, SP-A and SP-B, and inducing protein-associated nitro-tyrosine. Exposure of animals for prolonged periods (48 to 72 hours) to inhaled NO (80 to 120 ppm) has been associated with a decrease in surface activity. This is caused by binding of surfactant to iron-proteins that are modified by NO (particularly methemoglobin), or by peroxynitrite induced damage of surfactant. In contrast, exposure of isolated surfactant complex to NO during surface cycling strikingly decreases the inactivation of surfactant, preventing the conversion of surfactant to small vesicles that are no longer surface-active, and preventing lipid peroxidation. This finding is consistent with the function of NO as a lipid-soluble chain-braking antioxidant. It is possible that this lipophilic gas has as yet undefined roles in regulation of surfactant metabolism and maintenance of surface activity. Deficiency in pulmonary NO may be present during the early neonatal period in respiratory distress syndrome and in persistent fetal circulation. The premature lung is likely to be sensitive to NO toxicity that may include lung damage, abnormal alveolarization, and mutagenicity. Defining of the indications, the dosage, and the toxicity of inhaled NO therapy remains the challenge for experimental and clinical research.

References (101)

  • GriscavageJM et al.

    Nitric oxide inhibits neuronal nitric oxide synthase by interacting with the heme prosthetic group

    J Biol Chem

    (1994)
  • PerrellaMA et al.

    Transforming growth factor-1 β, but not dexamethasone, down-regulates nitric-oxide synthase mRNA after its induction by Interleukin-1 β in rat smooth muscle cells

    J Biol Chem

    (1994)
  • BauerJA et al.

    Endogenous nitric oxide in expired air: Effects of acute excercise in humans

    Life Sci

    (1994)
  • FinerNN et al.

    Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: Dose response

    J Pediatr

    (1994)
  • RubboH et al.

    Nitric Oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation

    J Biol Chem

    (1994)
  • IschiropoulosH et al.

    Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase

    Arch Biochem Biophys

    (1992)
  • FrankL

    Antioxidants, nutrition, and bronchopulmonary dysplasia

    Clin Perinatol

    (1992)
  • RobbinsRA et al.

    Expression of inducible nitric oxide in human lung epithelial cells

    Biochem Biophys Res Commun

    (1994)
  • FreemanBA et al.

    Hyperoxia increases oxygen radical production in rat lungs and lung mitochondria

    J Biol Chem

    (1981)
  • MüllerB et al.

    Effect of nitrogen dioxide inhalation on surfactant phosphatidylcholine synthesis in rat alveolar type II cells

    Biochim Biophys Acta

    (1993)
  • MoncadaS et al.

    The L-arginine-nitric oxide pathway

    N Engl J Med

    (1992)
  • CulottaE et al.

    NO news is good news

    Science

    (1992)
  • KerwinJF et al.

    The arginine-nitric oxide pathway: A target for new drugs

    Med Res Rev

    (1994)
  • SnyderSH

    Nitric oxide: First in a new class of neurotransmitters?

    Science

    (1992)
  • AbmanSH et al.

    Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth

    Am J Physiol

    (1990)
  • BredtDS et al.

    Nitric Oxide: A Physiologic Messenger Molecule

    Annu Rev Biochem

    (1994)
  • KourembanasS

    Hypoxic responses of the neonatal endothelium

    Semin Perinatol

    (1992)
  • MupanemundaRH et al.

    Treatment of newborn infants with inhaled nitric oxide

    Arch Dis Child

    (1995)
  • BeckmanJS et al.

    Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and super-oxide

    Proc Natl Acad Sci USA

    (1990)
  • HuieRE et al.

    The reaction rate of nitric oxide with superoxide

    Free Rad Res Commun

    (1993)
  • StamlerFH et al.

    Biochemistry of nitric oxide and its redox-activated forms

    Science

    (1992)
  • GastonB et al.

    The biology of nitrogen oxides in the airways

    Am J Crit Care Med

    (1994)
  • KwonNS et al.

    Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide

    J Exp Med

    (1991)
  • HenryY et al.

    Nitric oxide: A biological effector: electron paramagnetic resonance detection of nitrosyl-iron-protein complexes in whole cells

    Eur Biophys J

    (1991)
  • GrangerDL et al.

    Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells

    J Cell Biol

    (1982)
  • WelshN et al.

    Interleukin-1 β-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase

    Endocrinology

    (1991)
  • GengY et al.

    Interferon-γ and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells

    Circ Res

    (1992)
  • BeckmanJS et al.

    Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and super-oxide

    Proc Natl Acad Sci USA

    (1991)
  • World Health Organization
  • ZwemerFL et al.

    Silo filler's disease in New York state

    Am Rev Respir Dis

    (1992)
  • HalliwellB et al.

    Free radicals, antioxidants, and human disease: Where are we now

    J Lab Clin Med

    (1992)
  • PryorWA et al.

    One- and two-electron oxidations of methionine by peroxynitrite

    Proc Natl Acad Sci USA

    (1994)
  • WinkDA et al.

    DNA deaminating ability and genotoxicity of nitric oxide and its progenitors

    Science

    (1991)
  • MyersPR et al.

    Effects of cytokines tumor necrosis factor α and interleukin 1 β on endotoxin-mediated inhibition of endotheliumderived relaxing factor bioactivity and nitric oxide production in vascular endothelium

    Shock

    (1994)
  • SzaboC et al.

    Attenuation of the induction of nitric oxide synthase by endognous glucocorticoids accounts for endotoxin tolerance in vivo

    Proc Natl Acad Sci USA

    (1994)
  • WeissG et al.

    Iron regulates nitric oxide synthase activity by controlling nuclear transcription

    J Exp Med

    (1994)
  • OswaldIP et al.

    IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity

    J Immunol

    (1992)
  • AsanoK et al.

    Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells

    Proc Natl Acad Sci USA

    (1994)
  • RobbinsCG et al.

    In vitro and in vivo effects of inhaled nitric oxide (NO) and hyperoxia on surfactant function

    Pediatr Res

    (1994)
  • MasonRJ

    Surfactant secretion

  • Cited by (43)

    • The impact of staphylococcal mastitis on the level of milk IL-6, lysozyme and nitric oxide

      2010, Comparative Immunology, Microbiology and Infectious Diseases
      Citation Excerpt :

      The significantly increased production of NO in the clinically mastitic cows could be intimately correlated with the production of staphylococcal enterotoxin C [13]. The increased production of NO and IL-6 which are produced during clinical mastitis under the influence of staphylococcal enterotoxin β [13] and [42] causes down regulation of CYP450 which consequently leads to oxidative damage of the mammary gland in S. aureus-induced mastitis [13,48–51]. Worldwide, a lot of effort has been focused on how to minimize the effects of subclinical and chronic mastitis, for example by preventing intramammary infection using vaccines, or to eliminate ongoing infections by treatment with antibiotics, or to stimulate the immune system of an animal with non-specific immunomodulators.

    • Effect of antioxidants on apoptosis and cytokine release in fetal rat Type II pneumocytes exposed to hyperoxia and nitric oxide

      2004, Cytokine
      Citation Excerpt :

      So, while NO may be a critical intermediary in the production of oxidant tissue damage [18], NO-dependent protective effects have been observed in processes where oxidant injury has been proposed to play an etiological role [20–22]. A probable explanation for these differing results is that NO is a free radical with both AO and pro-oxidant properties—a molecular chameleon [23]. The dose and duration of exposure to exogenous NO, in the presence or absence of hyperoxia, may determine its beneficial or detrimental role.

    • Physiology of Nitric Oxide in the Developing Lung

      2003, Fetal and Neonatal Physiology: Third Edition
    View all citing articles on Scopus
    View full text